Delphine Charvin, founding CEO, and Mélanie Rouillier, founding COO, have been selected by EY Grand Est as candidates for the 2026 Entrepreneur of the Year Award.

Elkedonia contributes to the EBRAINS 10-year roadmap, bringing its precision psychiatry drug development expertise to the future of European brain research.

Elkedonia appoints industry veteran Pierre d’Epenoux, former CEO of ImCheck Therapeutics, as Independent Chairman to strengthen its Board of Directors. This leadership addition supports the company's growth as it advances its innovative, non-hallucinogenic neuroplastogens targeting the…

Elkedonia joined the UK-French Mental Health Biomarkers consortium at the French Embassy in London, strengthening cross-border collaboration on mental health.

Elkedonia’s founding CEO has been selected to join the prestigious program by BNP Paribas and The Galion Project, an honor that places her among an inspiring community of leading founders. This selection highlights Delphine's leadership and…

Jocelyne Caboche took part in the second edition co-organised by the Alliance pour la Santé Mentale and the Fondation pour la Recherche Médicale, contributing to a working group on mental health research.

Exactly one year ago, on March 20th, 2025 (International Day of Happiness) Elkedonia was born. A meaningful coincidence for a Franco-Belgian biotech dedicated to rewiring resilience and bringing hope to patients with depression. What an incredible…

Delphine Charvin highlighted Elkedonia’s pioneering neuroplastogen approach and its patient-first strategy that leverages AI and biomarkers to overcome current antidepressant limitations. The panel underscored the company's commitment to putting patients at the heart of neuropsychiatric research…

BioCentury This Week highlighted Elkedonia among 2026's neuro companies to watch, profiling the French biotech, alongside U.S.-based Bexorg, in its Emerging Company Profile series.

Elkedonia concludes a successful year marked by major scientific milestones in its non-hallucinogenic approach to depression and the assembly of a world-class expert team. These solid foundations in precision medicine set the stage for accelerated impact…

BioCentury has selected Elkedonia as a featured "Emerging Company" validating its first-in-class approach targeting the ELK1 protein to treat depression without hallucinogenic side effects. This recognition highlights Elkedonia’s unique ability to drive neuroplasticity downstream of neurotransmitters,…

Elkedonia is featured by Bpifrance Le Hub for its commitment to developing rapid-acting, home-administered antidepressants without side effects for patients with treatment-resistant depression. By reintegrating biology into neuropsychiatry, the company aims to provide urgent new therapeutic…

Elkedonia was invited to speak at the 14th edition of BioFIT Event BioFIT is the place to be for early-stage deals in the LifeSciences sector in Europe.

Swiss HLG partnered with Roche to host the annual Basel networking event—and it was a showcase of innovation and collaboration. We explored cutting-edge topics in Neuroscience, including breakthroughs in ALS research, innovative biomarkers, and the fascinating…

Jocelyne Caboche was invited as a speaker to the first edition on mental health research, co-organised by the Alliance pour la Santé Mentale and the Fondation pour la Recherche Médicale, building solutions for tomorrow's mental health.

Based in Strasbourg’s dynamic ecosystem, Elkedonia is featured in Le Journal des Entreprises for its innovative role in the Grand Est region. This supportive environment fuels their mission to transform depression care through cutting-edge health solutions.

Elkedonia has been named a finalist for the "Seed Raise of the Year" at the LSX European Lifestars Awards. This category celebrates companies that achieved the most impactful and transformative seed-stage fundraises in the life sciences…

Delphine Charvin will join a high-level panel at BIC2025 to share Elkedonia’s fundraising journey and pioneering neuroplastogen approach to neuropsychiatry. The session offers a unique look at driving biotech innovation and mental health breakthroughs in today's…

In a recent interview with Inside Precision Medicine, Delphine Charvin, discusses her journey as a neuroscientist and entrepreneur, and how Elkedonia is developing a non-addictive, non-hallucinogenic antidepressant targeting the Elk-1 protein.

Elkedonia is ranked among the top 15 seed-funded startups of June 2025 according to data from Crunchbase. The company successfully secured over $12.8 million in funding, solidifying its position as a significant player in this month's…

Delphine Charvin, CEO and co-founder of Elkedonia, was the guest of Sandra Gandoin on BFM Business, on July 15 2025. She discussed her company’s new antidepressant treatment approach, which is different from what is available today,…

🧠 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘄𝗲 𝗰𝗼𝘂𝗹𝗱 𝘁𝗿𝗲𝗮𝘁 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝗼𝘂𝘁? With over 300 million people affected globally—and 1 in 3 not responding to current treatments—treatment-resistant depression is one of the biggest unmet needs in mental health.

We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly.

We’re thrilled to announce that Elkedonia has been selected to join the Pre-Seed Showcase next week at the 25th Bio€quity Europe Conference - the leading investor gathering for the biotech community in Europe. BioCentury Inc. Elkedonia is a…

A new report studied depression levels across Europe and in older and younger individuals, with the outlook for France looking particularly poor. France may have had the highest pre-pandemic depression level among European countries, according to…

Elkedonia congratulates its Scientific Advisory Board President, Dr Jocelyne Caboche, who was honoured at Alliance Sorbonne University's Innovation Trophies for her contribution to advancing research and innovation.